{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:03:52Z","timestamp":1766268232084,"version":"build-2065373602"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin 4 and 6 dependent kinase inhibitors (CDK4\/6i) have recently been approved for postmenopausal women diagnosed with hormone receptor\u2013positive and HER2-negative metastatic breast cancer in combination with endocrine therapy. Research on the interaction of CDK4\/6i and radiotherapy are scarce, but we observed some unexpected and severe toxicity, such as interstitial lung disease (ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases<\/jats:title>\n                    <jats:p>Through blocking the transition from the G1 phase to the S phase (DNA synthesis phase), CDK4\/6i inhibit tumor cell proliferation. The most common adverse event is neutropenia. Gastrointestinal toxicity, fatigue, QT Interval prolongation, increased liver enzymes, venous thromboembolic events, and ILD. Although ILD is very unlikely to occur, if suspected (e.g., worsening cough, dyspnea), interrupt treatment immediately and to evaluate the patient. In this study, we reported two cases of ILD in patients treated with the combination of radiotherapy and CDK4\/6i. We also detailed the management strategy for patients who developed ILD, along with the subsequent clinical course and outcomes. Ultimately, with prompt and effective management, both patients showed improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases suggest that CDK4\/6i may potentiate radiotherapy-associated pulmonary toxicity, and clinicians should exercise caution with this combination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1661867","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:53Z","timestamp":1761888293000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Interstitial lung disease following combined CDK4\/6 inhibitor therapy and radiotherapy in advanced breast cancer: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Lanlan","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiquan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ctro.2020.11.010","article-title":"CDK 4\/6 inhibitors combined with radiotherapy: a review of literature","volume":"26","author":"Bosacki","year":"2021","journal-title":"Clin Transl Radiat Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cells8040321","article-title":"Updates on the CDK4\/6 inhibitory strategy and combinations in breast cancer","author":"Sobhani","year":"2019","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women With HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine","volume":"35","author":"Sledge GW","year":"2017","journal-title":"Ther J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A phase I study of the cyclin-dependent kinase 4\/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas","volume":"22","author":"Infante","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Canc Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/bjc.2011.177","article-title":"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1)","volume":"104","author":"Schwartz","year":"2011","journal-title":"Br J Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"B17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","article-title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","volume":"21","author":"Tolaney","year":"2020","journal-title":"Lancet Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.breast.2021.05.008","article-title":"de la Haba-Rodr\u00edguez J, Ciruelos E, Tolosa P, et al. The role of CDK4\/6 inhibitors in early breast cancer","volume":"58","author":"Gil-Gil","year":"2021","journal-title":"Breast."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2018.07.010","article-title":"Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response","volume":"102","author":"Huang","year":"2018","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.18632\/oncotarget.26652","article-title":"Abemaciclib: a multi-functional radiation modifier","volume":"10","author":"Naz","year":"2019","journal-title":"Oncotarget."},{"key":"B26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.adro.2019.03.011","article-title":"Safety and efficacy of palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination","volume":"4","author":"Chowdhary","year":"2019","journal-title":"Adv Radiat Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.radonc.2017.09.010","article-title":"Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients","volume":"126","author":"Hans","year":"2018","journal-title":"Radiother Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","article-title":"Dell'Aquila E, Petrianni GM, Tonini G, et al. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity","volume":"46","author":"Ippolito","year":"2019","journal-title":"Breast"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.08.096","article-title":"Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer","volume":"42","author":"Meattini","year":"2018","journal-title":"Breast."},{"key":"B30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2020.38.15_suppl.562","article-title":"Impact of metastases directed radiation therapy on CDK4\/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+\/HER2- breast cancer (MBC)","volume":"38","author":"Meattini","year":"2020","journal-title":"J Clin Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"10781552221107532","DOI":"10.1177\/10781552221107532","article-title":"Alpelisib induced interstitial lung disease in a patient with advanced breast cancer","volume":"2022","author":"Isiklar","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B32","volume-title":"Drug-Induced Interstitial Lung Disease During Cancer Therapies: Expert Opinion on Diagnosis and Treatment","author":"Conte","year":""},{"key":"B33","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cancers13051052","article-title":"Drug-related pneumonitis in cancer treatment during the COVID-19 era","volume":"13","author":"Cherri","year":"2021","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment","volume":"186","author":"Raschi","year":"2021","journal-title":"Breast Cancer Res Treat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12931-020-01433-w","article-title":"CDK4\/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis","volume":"21","author":"Birnhuber","year":"2020","journal-title":"Respir Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1661867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:24:54Z","timestamp":1761888294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1661867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":35,"alternative-id":["10.3389\/fmed.2025.1661867"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1661867","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1661867"}}